Cidara Therapeutics Inc (NASDAQ: CDTX) closed the day trading at $0.88 down -18.22% from the previous closing price of $1.07. In other words, the price has decreased by -$0.1950 from its previous closing price. On the day, 1660628 shares were traded.
Ratios:
For a better understanding of CDTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Tari Leslie sold 21,029 shares for $0.67 per share. The transaction valued at 14,085 led to the insider holds 258,681 shares of the business.
Sandison Taylor sold 20,662 shares of CDTX for $13,839 on Mar 11 ’24. The Chief Medical Officer now owns 347,095 shares after completing the transaction at $0.67 per share. On Mar 11 ’24, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 20,473 shares for $0.67 each. As a result, the insider received 13,713 and left with 198,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 95.15M and an Enterprise Value of 50.84M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.40 while its Price-to-Book (P/B) ratio in mrq is 9.84. Its current Enterprise Value per Revenue stands at 0.90 whereas that against EBITDA is -1.67.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $1.48, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 0.7489, while the 200-Day Moving Average is calculated to be 0.8526.
Shares Statistics:
Over the past 3-months, CDTX traded about 664.75K shares per day on average, while over the past 10 days, CDTX traded about 1.43M shares per day. A total of 90.62M shares are outstanding, with a floating share count of 81.35M. Insiders hold about 10.23% of the company’s shares, while institutions hold 29.71% stake in the company. Shares short for CDTX as of Mar 15, 2024 were 179.47k with a Short Ratio of 0.27, compared to 463.32k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.20% and a Short% of Float of 0.20%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.16, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.28 and -$0.36 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.58, with 3 analysts recommending between -$0.38 and -$0.7.
Revenue Estimates
3 analysts predict $11.54M in revenue for the current quarter. It ranges from a high estimate of $14M to a low estimate of $6.7M. As of the current estimate, Cidara Therapeutics Inc’s year-ago sales were $10.22M, an estimated increase of 12.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $13.05M, a decrease of -49.80% less than the figure of $12.90% in the same quarter last year. There is a high estimate of $14.5M for the next quarter, whereas the lowest estimate is $11.6M.
A total of 3 analysts have provided revenue estimates for CDTX’s current fiscal year. The highest revenue estimate was $60.3M, while the lowest revenue estimate was $53M, resulting in an average revenue estimate of $57.85M. In the same quarter a year ago, actual revenue was $64.29M, down -10.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $21.07M in the next fiscal year. The high estimate is $29.5M and the low estimate is $5.8M. The average revenue growth estimate for next year is down -63.60% from the average revenue estimate for this year.
